NewAmsterdam Pharma (NAMS) Goodwill & Intangibles (2022 - 2026)

NewAmsterdam Pharma has reported Goodwill & Intangibles for 5 years, with the latest figure at $375000.0 in Q1 2026.

• Quarterly Goodwill & Intangibles fell 25.3% year-over-year to $375000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $375000.0 (down 25.3% YoY) and the FY2025 annual result came in at $407000.0, down 23.78% from the prior year.
• Goodwill & Intangibles slipped to $375000.0 in Q1 2026 per NAMS's latest filing, from $407000.0 in the prior quarter.
• Over five years, Goodwill & Intangibles peaked at $88.9 million in Q2 2023 and troughed at $170000.0 in Q4 2023.
• A 5-year average of $14.9 million and a median of $494000.0 in 2024 frame the typical range for Goodwill & Intangibles.
• The sharpest annual moves came in 2023 and 2024: Goodwill & Intangibles slumped 99.8% in 2023, then surged 214.12% in 2024.
• Over 5 years, Goodwill & Intangibles stood at $84.8 million in 2022, then plunged by 99.8% to $170000.0 in 2023, then soared by 214.12% to $534000.0 in 2024, then dropped by 23.78% to $407000.0 in 2025, then decreased by 7.86% to $375000.0 in 2026.
• According to Business Quant data, Goodwill & Intangibles over the past three periods registered $375000.0, $407000.0, and $439000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.